STOCKHOLM--(BUSINESS WIRE)--SciBase, a Swedish medtech company that develops and markets a new method for early detection of malignant melanoma, has received approval from the United States Patent and Trademark Office (USPTO) regarding its patent application for its electrodes with micro-needles. The method is already approved in 12 European countries, Australia and Canada. All patents are valid through 2023.
SciBase’s solution Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Malignant melanoma is a fast growing kind of skin cancer, which appears in the epidermis right under the cornified layer. Nevisense’s electrodes are equipped with microscopic needles that measure the electric impedance in the cells below, where malignant melanoma appears. The technique is essential for detecting the early stages of skin cancer.
”Right now, Nevisense is in the approval process for sales and marketing in the United States, which is a future key market for us. The approval of our patent is thus an important step in our global expansion. Electrodes with micro-needles can potentially be used to detect other types of cancer as well,” says Simon Grant, CEO of SciBase.
SciBase holds a total of 49 registered patents and currently have another 12 active patent applications pending in six patent families.
Skin cancer is the most common cancer in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75 percent) of deaths related to skin cancer, although it only accounts for 4 percent of all skin cancer cases. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly. The key to management is early detection.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a technology called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Further is available on www.scibase.com.
This information was brought to you by Cision http://news.cision.com
SciBase AB
Simon Grant, CEO
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com
Help employers find you! Check out all the jobs and post your resume.
